Physician profile
David C Ball
NPI 1093714776
$3,191.36
in general payments reported to CMS, 2019-2025
21 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $220 · 2021: $313 · 2022: $368 · 2023: $538 · 2024: $855 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.58 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,012.94 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Glaukos Corporation | $361.98 | 2019-2024 | Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $263.92 | 2019-2021 | |
| Allergan, INC. | $241.35 | 2019-2022 | |
| Alcon Vision LLC | $222.34 | 2019-2025 | Rocklatan, Eysuvis, Clareon |
| Bausch & Lomb Americas INC. | $197.94 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sight Sciences, INC. | $148.47 | 2021-2022 | |
| New World Medical,INC. | $119.45 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $95.19 | 2024 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $84.96 | 2023-2024 | Acthar |
| Horizon Therapeutics Plc | $81.82 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $71.52 | 2020-2025 | |
| Amgen INC. | $52.61 | 2024-2025 | Tepezza |
| Rxsight INC | $42.54 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Dompe US, INC. | $40.24 | 2025 | Oxervate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $36.75 | 2022-2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $35.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.57 | 2023 | |
| Thea Pharma INC. | $23.28 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $13.14 | 2019 | |
| Shire North American Group INC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.